Pfizer is pleased to announce the 2011 ASPIRE Young Investigator Competitive Research Grant Awards: MRSA Clinical Research in Specific Patient Populations and Infection Types

Mission

Support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis, treatment and prevention of infections.

Background

Previous ASPIRE programs have supported laboratory based projects (in vitro, in vivo) evaluating MRSA pathogenesis and host response. In contrast, the focus of ASPIRE 2011 is to evaluate anti-infective therapies including linezolid in defined patient populations with specific infections through submission of innovative research proposals.

Young Investigators

The ASPIRE Program demonstrates Pfizer’s commitment to supporting promising young investigators with an interest in advancing knowledge in defined areas including infectious diseases and antibacterial research.

Request for Proposals

Pfizer invites academic leaders to nominate junior faculty to apply for the 2011 ASPIRE Young Investigator Awards in Antibacterial Research through submission of innovative research proposals that evaluate the impact of anti-infective therapies including linezolid in defined patient populations with specific infection types.

2011 Research Topic

MRSA Clinical Research in Specific Patient Populations and Infection Types
Although considerable clinical trial data exists for linezolid, knowledge gaps remain in various patient populations noted below. It is hoped the resulting data will lead to a better understanding of the safety and efficacy of linezolid to enhance the clinical care of patients with bacterial infections.

Research Requirements

An applicant should have a strong academic career interest within the areas of focus and should consider the following components when developing their research proposals:

A. Clinical evaluations of anti-infective therapies including linezolid within the following infection types including new or recurrent infections due to MRSA B. Clinical evaluations of anti-infective therapies including linezolid within the following patient populations:

Research Expectations

Within the specified patient populations with infection types of interest, investigators are expected to:

Proposals should be clinical in design which may be limited to small exploratory studies and may include laboratory evaluations that attempt to test hypotheses or evaluations of impact on healthcare resource utilization. Prospective evaluations are preferred however, well-designed retrospective analyses may also be considered for inclusion into the overall proposal to generate and test hypotheses.

Available Awards

Pfizer is funding research awards up to a maximum of $100,000 USD/CDN each for one year to conduct clinical research generating data that will lead to a better understanding of the safety and efficacy of linezolid to enhance the clinical care of patients with bacterial infections.

Deadline for Application